Pharmacotherapy for body dysmorphic disorder: Treatment received and illness severity

Annals of Clinical Psychiatry

Volumn 18, Issue 4, 2006, Pages 251-257

  Phillips, Katharine A ^a,b   Pagano, Maria E ^b   Menard, William ^a  

^a BUTLER HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Body dysmorphic disorder; Medications; Pharmacotherapy; Somatic treatment; Somatoform disorders

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; BENZODIAZEPINE; BUSPIRONE; CENTRAL STIMULANT AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BODY DYSMORPHIC DISORDER; DISEASE SEVERITY; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NATURALISTIC INQUIRY; PRESCRIPTION; PRIORITY JOURNAL; SOMATOFORM DISORDER; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BENZODIAZEPINES; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; COMORBIDITY; DELUSIONS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PSYCHOTROPIC DRUGS; SEROTONIN UPTAKE INHIBITORS; SOMATOFORM DISORDERS; TREATMENT OUTCOME;

EID: 33845651179     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: 10.1080/10401230600948464     Document Type: Article

References (40)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Washington, DC: American Psychiatric Association, 1994
2. Phillips KA: Quality of life for patients with body dysmorphic disorder. J Nerv Ment Dis 2000; 188:170-175
3. Phillips KA, Diaz S: Gender differences in body dysmorphic disorder. J Nerv Ment Dis 1997; 185:570-577
4. Veale D, Boocock A, Gournay K, Dryden W, Shah F, Willson R, Wallburn J: Body dysmorphic disorder: A survey of fifty cases. Br J Psychiatry 1996; 169:196-201
5. Bienvenu OJ, Samuels JF, Riddle MA, Hoehn-Saric R, Liang KY, Cullen BA, Grados MA, Nestadt G: The relationship of obsessive-compulsive disorder to possible spectrum disorders: Results from a family study. Biol Psychiatry 2000; 48:287-293
6. Faravelli C, Salvatori S, Galassi F, Aiazzi L, Drei C, Cabras P: Epidemiology of somatoform disorders: A community survey in Florence. Soc Psychiatry Psychiatr Epid 1997; 32:24-29
7. Rief W, Buhlmann U, Wilhelm S, Borkenhagen A, Brahler E: The prevalence of body dysmorphic disorder: A population-based survey. Psychol Med 2006; 36:877-885
8. Grant JE, Kim SW, Crow SJ: Prevalence and clinical features of body dysmorphic disorder in adolescent and adult psychiatric inpatients. J Clin Psychiatry 2001; 62:517-522
9. Hollander E, Allen A, Kwon J, Aronowitz B, Schmeidler J, Wong C, Simeon D: Clomipramine vs desipramine crossover trial in body dysmorphic disorder. Arch Gen Psychiatry 1999; 56:1033-1039
10. Phillips KA, Albertini RS, Rasmussen SA: A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry 2002; 59:381-388
11. Phillips KA, Dwight MM, McElroy SL: Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry 1998; 59:165-171
12. Perugi G, Giannotti D, Di Vaio S, Frare F, Saettoni M, Cassano GB: Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). Int Clin Psychopharmacol 1997; 11:247-254
13. Phillips KA, Najar F: An open-label study of citalopram in body dysmorphic disorder. J Clin Psychiatry 2003; 64:715-720
14. Phillips KA, McElroy SL, Keck PE Jr., Pope HG Jr, Hudson JI: A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases. Psychopharmacol Bull 1994; 30:179-186
15. Hollander E, Cohen L, Simeon D, Rosen J, DeCaria C, Stein DJ: Fluvoxamine treatment of body dysmorphic disorder (letter). J Clin Psychopharmacol 1994; 14:75-77
16. March JS, Frances A, Carpenter D, Kahn DA: The expert consensus guideline series: Treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997; 58:1-72
17. Phillips KA: Pharmacologic treatment of body dysmorphic disorder: Review of the evidence and a recommended treatment approach. CNS Spectrums 2002; 7:453-460
18. Allen A, Hollander E: Body dysmorphic disorder. Psychiatr Clin North Am 2000; 23:617-628
19. Phillips KA, McElroy SL, Keck PE, Pope HG, Hudson JI: Body dysmorphic disorder: 30 cases of imagined ugliness. Am J Psychiatry 1993; 150:302-308
20. Hollander E, Cohen LJ, Simeon D: Body dysmorphic disorder. Psychiatric Ann 1993; 23:359-364
21. Phillips KA, Albertini RS, Siniscalchi JM, Khan A, Robinson M: Effectiveness of pharmacotherapy for body dysmorphic disorder: A chart-review study. J Clin Psychiatry 2001; 62:721-727
22. Phillips KA, Grant JE, Siniscalchi JM, Stout R, Price LH: A retrospective follow-up study of body dysmorphic disorder. Compr Psychiatry 2005; 46:315-321
23. Zimmerman M, Mattia JI: Body dysmorphic disorder in psychiatric outpatients: Recognition, prevalence, comorbidity, demographic, and clinical correlates. Compr Psychiatry 1998; 39:265-270
24. Grant JE, Kim SW, Eckert ED: Body dysmorphic disorder in patients with anorexia nervosa: Prevalence, clinical features, and delusionality of body image. Int J Eat Disord 2002; 32:291-300
25. Phillips KA, Nierenberg AA, Brendel G, Fava M: Prevalence and clinical features of body dysmorphic disorder in atypical major depression. J Nerv Ment Dis 1996; 184:125-129
26. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders: Non-patient edition (SCID-I N/P). New York: NYSPI, 1996
27. Phillips KA, Hollander E, Rasmussen SA, Aronowitz BR, DeCaria C, Goodman WK: A severity rating scale for body dysmorphic disorder: Development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacol Bull 1997; 33:17-22
28. National Institute of Mental Health: Special feature: rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull 1985; 21
29. Phillips KA, Grant J, Siniscalchi J, Albertini RS: Surgical and non-psychiatric medical treatment of patients with body dysmorphic disorder. Psychosomatics 2001; 42:504-510
30. Crerand C, Phillips KA, Menard W, Fay C: Non-psychiatric medical treatment of body dysmorphic disorder. Psychosomatics 2005; 46:549-555
31. Phillips KA: Psychosis in body dysmorphic disorder. J Psychiatr Res 2004; 38:63-72
32. Leon AC, Keller MB, Warshaw MG, Mueller TI, Solomon DA, Coryell W, Endicott J: Prospective study of fluoxetine treatment and suicidal behavior in affectively ill subjects. Am J Psychiatry 1999; 156:195-201
33. Warshaw MG, Keller MB: The relationship between fluoxetine use and suicidal behavior in 654 subjects with anxiety disorders. J Clin Psychiatry 1996; 57:158-166
34. Phillips KA, Siniscalchi JM, McElroy SL: Depression, anxiety, anger, and somatic symptoms in patients with body dysmorphic disorder. Psychiatr Quart 2004; 75:309-320
35. Saxena S, Winograd A, Dunkin JJ: A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive compulsive disorder. J Clin Psychiatry 2001; 62:67-72
36. Allen A, Hadley SJ, Kaplan A, Simeon D, Friedberg J, Priday L, Greenberg J, Hollander E: An open-label trial of venlafaxine in body dysmorphic disorder. Abstracts, Sixth International Obsessive Compulsive Disorder Conference, Lanzarote, Spain. 28; 2003
37. Phillips KA: The Broken Mirror: Understanding and Treating Body Dysmorphic Disorder. New York: Oxford University Press, 1996 (Revised and expanded edition, 2005)
38. Phillips KA: Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry 2005; 162:377-379
39. Phillips KA: Olanzapine augmentation of fluoxetine in body dysmorphic disorder (letter). Am J Psychiatry 2005; 162:1022-1023
40. Neziroglu F, Khemlani-Patel S: A review of cognitive and behavioral treatment for body dysmorphic disorder. CNS Spectrums 2002; 7:464-471